Switching Biological Therapies in Severe Asthma

Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Rα (Mepolizumab and Benralizumab), and anti-IL-4Rα (Dupilumab). Numerous randomized controlled trials (RCTs) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Scioscia, Giulia, Nolasco, Santi, Campisi, Raffaele, Quarato, Carla Maria Irene, Caruso, Cristiano, Pelaia, Corrado, Portacci, Andrea, Crimi, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253346/
https://www.ncbi.nlm.nih.gov/pubmed/37298514
http://dx.doi.org/10.3390/ijms24119563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253346/
https://www.ncbi.nlm.nih.gov/pubmed/37298514
http://dx.doi.org/10.3390/ijms24119563

Ejemplares similares